- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Jazz Pharmaceuticals PLC (JAZZ)
Assess today's live Jazz Pharmaceuticals PLC (JAZZ) share price, performance and insights using our live NASDAQ: JAZZ stock exchange data.
Analyse the historical data and Jazz Pharmaceuticals PLC share price performance charts on this page. Our technical summary section provides analysis on Jazz Pharma share price buy/sell indicators using real-time data (or discuss the Jazz Pharma (JAZZ) stock price today with other investors in the Jazz Pharma NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ JAZZ share price (ISIN: IE00B4Q5ZN47) to enhance your trading decisions with our free investment tools and resources.
What Is the Jazz Pharmaceuticals PLC Share Price Today?
The Jazz Pharma share price today is 168.07.
What Is the Stock Symbol for Jazz Pharmaceuticals PLC
The stock symbol (or 'ticker') for Jazz Pharmaceuticals PLC is "JAZZ."
What Stock Exchange Does Jazz Pharmaceuticals PLC Trade On?
Jazz Pharmaceuticals PLC is listed and trades on the NASDAQ stock exchange.
Is Jazz Pharmaceuticals PLC a Good Stock to Buy?
Determining whether Jazz Pharmaceuticals PLC—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Analyse the historical data and Jazz Pharmaceuticals PLC share price performance charts on this page. Our technical summary section provides analysis on Jazz Pharma share price buy/sell indicators using real-time data (or discuss the Jazz Pharma (JAZZ) stock price today with other investors in the Jazz Pharma NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ JAZZ share price (ISIN: IE00B4Q5ZN47) to enhance your trading decisions with our free investment tools and resources.
What Is the Jazz Pharmaceuticals PLC Share Price Today?
The Jazz Pharma share price today is 168.07.
What Is the Stock Symbol for Jazz Pharmaceuticals PLC
The stock symbol (or 'ticker') for Jazz Pharmaceuticals PLC is "JAZZ."
What Stock Exchange Does Jazz Pharmaceuticals PLC Trade On?
Jazz Pharmaceuticals PLC is listed and trades on the NASDAQ stock exchange.
Is Jazz Pharmaceuticals PLC a Good Stock to Buy?
Determining whether Jazz Pharmaceuticals PLC—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Currency in USD
167.93
-0.06(-0.03%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
167.63
168.63
52 wk Range
95.49
182.99
Earnings results expected in 6 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
167.63168.63
52 wk Range
95.49182.99
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
JAZZ Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
219.40
Upside
+30.65%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
High shareholder yield
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Jazz Pharma Company Profile
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Xyrem for the treatment of cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Defitelio to treat severe veno-occlusive disease; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab in Phase 3 trial to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Epidiolex in Phase 3 trial to treat LGS, DS, and TSC; Suvecaltamide in Phase 2 trial to treat Parkinson's disease tremor; JZP815, a pan-RAF kinase inhibitor in Phase 1 trial that targets components of the mitogen-activated protein kinase; JZP898, a conditionally activated interferon alpha molecule in Phase 1 trial; JZP441 in Phase 1 trial to treat narcolepsy, IH, and other sleep disorders; JZP324, an extended-release low sodium oxybate formulation in Phase 1 trial for patients with sleep disorders; and JZP150 to treat post-traumatic stress disorder. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
Jazz Pharmaceuticals PLC Earnings Call Summary for Q3/2025
- Jazz Pharmaceuticals exceeded Q3 expectations with EPS of $8.13 (37.1% above forecast) and revenue of $1.13 billion, despite a 0.44% stock decline in after-hours trading.
- Revenue grew 7% year-over-year, driven by strong performance of key products Xywav ($431M, +11%) and Epidiolex ($303M, +20%), reinforcing the company's position in rare disease markets.
- Management narrowed full-year revenue guidance to $4.175-$4.275 billion as the company prepares for potential generic competition in the sleep market in 2026.
- CEO Renee Gala highlighted two recent FDA approvals, while CFO Phil Johnson noted robust cash flow generation of nearly $1 billion in the first nine months of 2025.
- The company maintains a strong financial position with $2 billion in cash and investments, continuing its strategic expansion through the Chimerix acquisition and licensing agreements.
Last Updated: 05/11/2025, 23:06
Read Full TranscriptCompare JAZZ to Peers and Sector
Metrics to compare | JAZZ | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipJAZZPeersSector | |
|---|---|---|---|---|
P/E Ratio | −27.7x | 22.8x | −0.5x | |
PEG Ratio | 0.15 | 0.71 | 0.00 | |
Price/Book | 2.6x | 4.9x | 2.6x | |
Price / LTM Sales | 2.5x | 3.9x | 3.3x | |
Upside (Analyst Target) | 31.7% | −11.0% | 46.0% | |
Fair Value Upside | Unlock | 6.1% | 5.4% | Unlock |
Analyst Ratings
14 Buy
1 Hold
0 Sell
Ratings:
15 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 219.40
(+30.65% Upside)
Earnings
Latest Release
Nov 05, 2025
EPS / Forecast
8.13 / 5.93
Revenue / Forecast
1.13B / 1.11B
People Also Watch
FAQ
What Is the Jazz Pharma (JAZZ) Share Price Today?
The live Jazz Pharma share price today is 167.93
What Stock Exchange Does Jazz Pharma (JAZZ) Trade On?
Jazz Pharma is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Jazz Pharma?
The stock symbol (also called a 'ticker') for Jazz Pharma is "JAZZ."
What Is the Current Jazz Pharma Market Cap?
As of today, Jazz Pharma market capitalisation is 10.19B.
What Is Jazz Pharma's (JAZZ) Earnings Per Share (TTM)?
The Jazz Pharma EPS is currently -6.06 (Trailing Twelve Months).
When Is the Next Jazz Pharma Earnings Date?
Jazz Pharma's next earnings report will be released on 24/02/2026.
Is JAZZ a Buy or Sell From a Technical Analyst Perspective?
Based on today's Jazz Pharma moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Jazz Pharma Stock Split?
Jazz Pharma has split 0 times. (See the JAZZ stock split history page for full effective split date and price information.)
How Many Employees Does Jazz Pharma Have?
Jazz Pharma has 2800 employees.
What is the current trading status of Jazz Pharma (JAZZ)?
As of 18/02/2026, Jazz Pharma (JAZZ) is trading at a price of 167.93, with a previous close of 167.98. The stock has fluctuated within a day range of 167.63 to 168.63, while its 52-week range spans from 95.49 to 182.99.
What Is Jazz Pharma (JAZZ) Price Target According to Analysts?
The average 12-month price target for Jazz Pharma is USD219.40, with a high estimate of USD263 and a low estimate of USD188. 14 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +30.65% Upside potential.
What Is the JAZZ Premarket Price?
JAZZ's last pre-market stock price is 168.20. The pre-market share volume is 640.00, and the stock has decreased by 0.22, or 0.13%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.